Navigation Links
Full Year 2008 Results Date Notification - 19 February 2008
Date:2/9/2009

PHILADELPHIA and DUBLIN, Ireland, February 9 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce full year 2008 earnings on Thursday 19 February 2009.

    Results press release will be issued at:    12:00 GMT / 07:00 EST
    Investor meeting and conference call time:  14:00 GMT / 09:00 EST

Investor & Analyst meeting and conference call:

Angus Russell, Chief Executive Officer, Graham Hetherington, Chief Financial Officer, Mike Cola, President, Specialty Pharmaceuticals and Sylvie Gregoire, President, Human Genetic Therapies will host the investor and analyst meeting and conference call at 14:00 GMT/9:00 EST.

The meeting will take place at the offices of Deutsche Bank, Winchester House, 1 Great Winchester Street, London, EC2N 2DB.

Please email ssalah@shire.com to register to attend this meeting in London.

    The details of the conference call are as follows:

    UK and International dial in  +44(0)20-7806-1957
    US dial in:                      +1-718-354-1388
    Password/Conf ID:                        9465839

    Live Webcast:
http://www.shire.com/shire/InvestorRelations/quarterlyresults.jsp?tn=2&m1=48

Replay:

A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details are as follows:

    UK and International dial in:      +44(0)20-7806-1970
    US dial in                            +1-718-354-1112
    Pin code                                     9465839#

    Webcast replay:
http://www.shire.com/shire/InvestorRelations/quarterlyresults.jsp?tn=2&m1=48

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com


'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that its new website has gone ... story-driven, knowledge-based and mobile-friendly. Visit the new site: ... ... ... "The goal was to reimagine the ...
(Date:2/5/2016)... MANASSAS, Va. , Feb. 5, 2016 ... organization, is poised to assist the medical and life ... concerns around Zika Virus infection.   CDC ... --> Zika virus is a single-stranded ... also includes the West Nile, Dengue and Chikungunya Viruses. ...
(Date:2/5/2016)... SYDNEY , Feb. 5, 2016 Australian-US drug ... ), announced today the appointment of a new Chairman, Mr ... Bryce Carmine , effective immediately. James Garner ... an Executive Director and former Acting CEO, Mr Iain ... a Non-Executive Director. --> James Garner , has ...
(Date:2/4/2016)... (PRWEB) , ... February 04, 2016 , ... ... latest GC-MS and triple quad LC-MS, host live demos and poster sessions, and ... conference and exhibition. The conference takes place March 6 to 10 at the ...
Breaking Biology Technology:
(Date:2/1/2016)... , February 1, 2016 ... advancements to drive global touchfree intuitive gesture control market ... --> Rising sales of consumer electronics coupled with ... control market size through 2020 ... electronics coupled with new technological advancements to drive global ...
(Date:1/25/2016)... BLUE BELL, Pa. , Jan. 25, 2016   Unisys ... facial recognition system at John F. Kennedy (JFK) International Airport, ... and Border Protection (CBP) identify imposters attempting to enter ... or do not belong to them. pilot testing ... rolled out initially at three terminals at JFK during January 2016. ...
(Date:1/20/2016)... A market that just keeps on growing. ... explosion in genomics knowledge. Learn all about it in ... of dynamic trends are pushing market growth and company ... pharmacogenomics - pathogen evolution - next generation sequencing - ... understanding of the role of genetic material in Disease ...
Breaking Biology News(10 mins):